

Reference number(s) 2990-A

Specialty Guideline Management Mulpleta

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Mulpleta	lusutrombopag

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indication

Mulpleta is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: pretreatment platelet count.

Mulpleta SGM 2990-A P2024_R.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Prescriber Specialties

This medication must be prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist.

Exclusions

Coverage will not be provided when Mulpleta will be used concomitantly with other thrombopoietin receptor agonists (e.g., Doptelet, Promacta, Alvaiz, Nplate) or spleen tyrosine kinase inhibitors (e.g., Tavalisse).

Coverage Criteria

Thrombocytopenia in chronic liver disease

Authorization of 30 days may be granted for treatment of thrombocytopenia in members with chronic liver disease when both of the following criteria are met:

- Member has an untransfused platelet count of less than 50x109/L taken within 14 days of the request.
- Member is scheduled to undergo a procedure.

Continuation of Therapy

Continuation of therapy, defined as use beyond the initial approval for the same procedure, is not approvable. All members (including new members) requesting authorization due to newly scheduled procedure must meet all requirements in the coverage criteria.

Reference

Mulpleta [package insert]. Florham Park, NJ: Shionogi Inc.; April 2020.